Dalazatide TFA (C007B-349280)

Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and infAppearance:SolidIC50& Target:Kv1.3In Vitro:Dalazatide (ShK-186) (0-1000 pM) TFA blocks the Kv1.3 current in the Ova-specific GFP+ effector memory T (Tem) cells in a dose-dependent manner with a K d of 65 ± 5 pM. Dalazatide (0-100 nM; 3 days) TFA inhibits CCR7 − T cell proliferation in a dose-In Vivo:Dalazatide (ShK-186) (100 μg/kg; s.c.; once) TFA inhibits delayed-type hypersensitivity and suppresses the in vivo motility and activation of Tem cells in rats. MCE has not independently confirmed the accuracy of these methods. They are for referenceBiological Activity:Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inf. Specification: 0.98 Molecular Formula: C186H297F3N57PS7 Molecular Weight: 4556.1

UPC:

51111657

Condition:

New

Weight:

1.09 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

D659042-1mg

Product Size:

1mg